BioNexus Gene Lab Corp - 10-Q Filing

BioNexus Gene Lab Corp reports Q3 2026 results with updates on equity incentive plans and business segment performance. (Items: 3.02 of the Company’s Current Report on Form 8-K filed with the SEC on October 7, 2026)

SEC EDGAR ·

Tickers: $BGLC

Read the full article at SEC EDGAR

More Regulatory news